Related Experiment Video
Updated: Sep 13, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer
Rachael A Safyan1, E Gabriela Chiorean1
1University of Washington School of Medicine, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA, USA.
Abstract:
Pancreatic ductal adenocarcinoma (PDA) is highly aggressive and has few treatment options. To personalize therapy, it is critical to delineate molecular subtypes and understand inter- and intra-tumoral heterogeneity. KRAS mutations are present in 90 % of PDA, while 10 % are KRAS wild type and are potentially targetable with epidermal growth factor receptor (EGFR) blockade. KRASG12C inhibitors have shown activity in G12C mutated cancers, and novel G12D and pan-RAS inhibitors are in clinical trials. Fewer than 1 % of PDA harbor microsatellite instability high (MSI-High) status and are susceptible to immune checkpoint blockade. Albeit rare, and occurring in KRAS wild type PDAs, BRAF V600E mutations, HER2 amplification, and RET, NTRK, and NRG1 fusions are targetable with cancer agnostic FDA approved therapies. In this review, we highlight clinically relevant molecular alterations and clinical trials with focus on targeted therapies that can improve pancreatic cancer patients' outcomes through precision medicine.
Insights
Precision medicine offers new hope for pancreatic cancer patients by targeting specific molecular alterations. This review highlights key genetic mutations and emerging therapies for personalized pancreatic ductal adenocarcinoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive cancer with limited therapeutic options.
- Understanding molecular heterogeneity is crucial for developing personalized treatment strategies.
Purpose of the Study:
- To review clinically relevant molecular alterations in PDA.
- To highlight targeted therapies and ongoing clinical trials for improving patient outcomes.
Main Methods:
- Literature review of molecular alterations in PDA.
- Analysis of targeted therapies and FDA-approved treatments.
- Overview of ongoing clinical trials for novel agents.
Main Results:
- KRAS mutations are prevalent (90%), with specific inhibitors showing promise.
- KRAS wild-type PDA presents opportunities for EGFR blockade.
- Rare alterations like MSI-High, BRAF V600E, HER2 amplification, and gene fusions are targetable.
- Targeted therapies and immune checkpoint inhibitors offer new treatment avenues.
Conclusions:
- Personalized medicine approaches, focusing on molecular targets, are essential for advancing PDA treatment.
- Identifying specific mutations allows for the application of targeted therapies, potentially improving patient survival and outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...